Skip to main content

Table 4 Univariate linear COX regression assessing associations between parameters from 18F-FDG PET/CT and patient prognosis

From: Volumetric parameters on 18F-FDG PET/CT predict the survival of patients with gastric cancer associated with their expression status of c-MET

Variables PFS OS
HR P HR P
In all patients
 Gender
  Male 0.744 0.329 0.883 0.695
  Femalea 1.000   1.000  
 Age (years)
   ≥ 62 1.506 0.164 1.143 0.660
   < 62a 1.000   1.000  
 Pathological types
  WDA/MDA 1.252 0.447 1.103 0.749
  PDA/MAC/SRCa 1.000   1.000  
 Lauren classifications
  Intestinal 0.925 0.809 0.853 0.635
  Non-intestinala 1.000   1.000  
 Baseline CEA (ng/ml)
   ≥ 2.9 1.181 0.576 1.667 0.107
   < 2.9a 1.000   1.000  
 Baseline CA19–9 (U/ml)
   ≥ 9.0 1.537 0.162 1.632 0.138
   < 9.0a 1.000   1.000  
 Baseline CA72–4 (U/ml)
   ≥ 2.8 1.820 0.085 1.281 0.485
   < 2.8a 1.000   1.000  
 Findings on PET/CT
  Distant metastasis 5.009 <  0.001 3.236 0.001
  Locoregionala 1.000   1.000  
 SUVmax 1.065 0.004 1.059 0.013
 SUVpeak 1.079 0.005 1.071 0.017
 MTV 1.005 0.031 1.005 0.055
 TLG 1.001 0.031 1.001 0.072
In c-Met positive patients
 SUVmax 1.054 0.037 1.063 0.013
 SUVpeak 1.068 0.034 1.079 0.012
 MTV 1.009 0.013 1.015 0.001
 TLG 1.001 0.012 1.002 0.001
In c-Met negative patients
 SUVmax 1.055 0.188 1.013 0.775
 SUVpeak 1.071 0.161 1.015 0.799
 MTV 1.002 0.631 0.999 0.788
 TLG 1.000 0.897 0.999 0.478
  1. Note. CA19–9 carbohydrate antigen 19–9, CA72–4 carbohydrate antigen 72–4, CEA carcinoembryonic antigen, WDA well differentiated adenocarcinoma, MDA moderate differentiated adenocarcinoma, PDA poorly differentiated adenocarcinoma, SRC signet-ring cell carcinoma, MAC mucinous adenocarcinoma, PET/CT positron emission tomography/computed tomography, SUV standardized uptake value, Max maximum, MTV metabolic tumor volume, TLG total lesion glycolysis, PFS progression free survival, OS overall survival, HR hazards ratio. a, reference group
\